{
    "items": [
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-appoints-kasra-kasraian-phd-as-chief-technology-officer\" title=\"PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer\" class=\"state-published\">PepGen appoints Kasra Kasraian, PhD, as Chief Technology Officer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">19 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as well as cell and gene therapies.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/alchemab-therapeutics-signs-landmark-415m-licensing-agreement-for-atlx-1282-with-eli-lilly-and-company\" title=\"Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company\" class=\"state-published\">Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">5 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab\u2019s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/uploid-biotechnologies-selected-for-prestigious-merck-corporate-accelerator-programme-to-advance-women2019s-health-innovation\" title=\"U\u2011Ploid Biotechnologies selected for prestigious Merck Corporate Accelerator Programme to advance women\u2019s health innovation\" class=\"state-published\">U\u2011Ploid Biotechnologies selected for prestigious Merck Corporate Accelerator Programme to advance women\u2019s health innovation</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">1 May 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">U\u2011Ploid, a biotechnology company developing first-in-class therapeutics to address age-related infertility, today announced its selection for the inaugural Merck Corporate Accelerator. The programme, launched by EMD Serono in partnership with the Society for Innovation and Startups (SIS), is designed to support breakthrough innovation in women\u2019s health by providing funding, expert mentorship, and access to Merck\u2019s global network of scientific and clinical leaders.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-strengthens-senior-leadership-with-key-executive-and-board-appointments-alongside-acceleration-of-multiple-t-cell-engager-programs\" title=\"Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs\" class=\"state-published\">Enara Bio strengthens senior leadership with key Executive and Board appointments alongside acceleration of multiple T-Cell engager programs</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 April 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Enara Bio, a biopharmaceutical company pioneering the development of bispecific T-cell engagers directed against Dark Antigen\u00ae and other emerging targets, today announces the appointment of Stacey Davis as Chief Business Officer (CBO) and Chief Financial Officer (CFO). Her appointment strengthens the leadership team at a key moment for Enara as it prepares to transition its lead assets towards clinical development. Stacey most recently served as CBO at Xilio Therapeutics, where she was the architect of a series of major pharma collaborations. In total, Stacey brings over 25 years of experience in delivering growth, innovation, and strategic transformation in the biotech and pharmaceutical industries.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/orfonyx-bio-2013-big-ambitions-in-protein-upregulation\" title=\"Orfonyx Bio \u2013 big ambitions in protein upregulation\" class=\"state-published\">Orfonyx Bio \u2013 big ambitions in protein upregulation</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=company-insights\" title=\"Company insights\">\n\t\t                <span class=\"label label-primary\">Company insights</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">9 April 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Orfonyx Bio is looking to make its mark as a leader in protein upregulation for clinical benefit \u2013 and has made technical progress towards this goal over the past two years. In that time as a BioEscalator tenant the University of Oxford spin-out has also grown from two to seven employees, raised an Oxford Science Enterprises-backed seed round and started to understand where its approach might have the greatest clinical impact. Now it\u2019s raising additional funding.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/infinitopes-granted-phase-i-iia-clinical-trial-application-approval-to-evaluate-precision-vaccine-targeting-early-stage-oesophageal-cancer\" title=\"Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer\" class=\"state-published\">Infinitopes granted Phase I/IIa Clinical Trial Application approval to evaluate precision vaccine targeting early-stage oesophageal cancer</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">8 April 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Infinitopes Ltd today announces that the UK Medicines and Healthcare products RegulatoryAgency (MHRA) has granted Clinical Trial Application (CTA) approval for the first-in-humanPhase I/IIa clinical trial of ITOP1, the company\u2019s lead \u2018off-the-shelf\u2019 cancer vaccine. ITOP1 is a precision cancer vaccine, designed to safely and accurately target tumour antigens, leveraging the company\u2019s vector delivery system, aiming to drive strong and durable T-cell protection for patients with surgically resectable oesophageal adenocarcinoma (OAC).</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/care-fertility-and-u-ploid-biotechnologies-announce-research-collaboration-to-improve-egg-quality-in-women-of-advanced-maternal-age\" title=\"Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age\" class=\"state-published\">Care Fertility and U-Ploid Biotechnologies announce research collaboration to improve egg quality in women of advanced maternal age</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">7 April 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Care Fertility, a leading fertility treatment provider, and U-Ploid Biotechnologies, a pioneering reproductive health biotech, today announces a research collaboration aimed at improving egg quality and improve fertility treatment. Egg quality is one of the main contributing factors to infertility and is known to deteriorate rapidly with increasing female age. This research collaboration has the potential to validate novel therapeutics and offer hope to millions struggling to conceive.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/dr-mary-vinson-joins-the-u-ploid-as-clinical-development-advisor\" title=\"Dr Mary Vinson joins the U-Ploid as Clinical Development Advisor\" class=\"state-published\">Dr Mary Vinson joins the U-Ploid as Clinical Development Advisor</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">5 April 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Dr Vinson brings over 25 years of invaluable experience in the pharma and biotech industry, with a proven track record of leading and contributing to breakthrough therapeutics.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/pepgen-announces-appointment-of-two-new-directors-to-its-board\" title=\"PepGen announces appointment of two new directors to its Board\" class=\"state-published\">PepGen announces appointment of two new directors to its Board</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">30 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive experience in the life sciences to the Company.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-named-one-of-times-top-greentech-companies-in-2025\" title=\"Moa named one of TIME's top greentech companies in 2025\" class=\"state-published\">Moa named one of TIME's top greentech companies in 2025</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">26 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa recognised as leading global innovator in environmental impact.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/moa-technology-forms-new-biological-partnership-with-naicons\" title=\"Moa forms new biological partnership with NAICONS\" class=\"state-published\">Moa forms new biological partnership with NAICONS</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">25 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Moa and NAICONS join forces to discover the next generation of naturally-occurring herbicides.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/infinitopes-strengthens-board-with-two-biotech-leaders-to-advance-precision-immunotherapies-into-the-clinic\" title=\"Infinitopes strengthens Board with two biotech leaders to advance precision immunotherapies into the clinic\" class=\"state-published\">Infinitopes strengthens Board with two biotech leaders to advance precision immunotherapies into the clinic</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">20 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Infinitopes welcomes Jo Brewer, PhD (CSO at Adaptimmune), and Dan Menichella (former CEO and CBO of CureVac's US subsidiary) as incoming Non-Executive Directors, bringing deep expertise in immunotherpay and oncology innovation.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/the-gender-advantage-building-inclusive-and-thriving-ventures\" title=\"The Gender Advantage: Building Inclusive and Thriving Ventures\" class=\"state-published\">The Gender Advantage: Building Inclusive and Thriving Ventures</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-news\" title=\"BioEscalator news\">\n\t\t                <span class=\"label label-primary\">BioEscalator news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">20 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">To celebrate International Women's Day 2025, the BioEscalator was delighted to host a double panel discussion and networking event with EnSpire Oxford and Advanced Oxford.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/entelo-bio-ushering-in-new-ways-of-doing-science\" title=\"Entelo Bio ushering in new ways of doing science\" class=\"state-published\">Entelo Bio ushering in new ways of doing science</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">12 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Entelo Bio, a venture backed biotechnology company pioneering the emerging isoform frontier of medicine, releases Flow Agent, an adaptive agentic (autonomous, AI-driven) based workflow management framework for bioinformatics workflows.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/bioescalator-bulletin-spring-2025\" title=\"BioEscalator Bulletin - Spring 2025\" class=\"state-published\">BioEscalator Bulletin - Spring 2025</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-bulletin\" title=\"BioEscalator bulletin\">\n\t\t                <span class=\"label label-primary\">BioEscalator bulletin</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">11 March 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Stay updated with the latest BioEscalator updates, tenant and alumni news, and upcoming events in the Spring 2025 edition of the BioEscalator Bulletin.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/omass-therapeutics-appoints-birgitte-volck-as-non-executive-director\" title=\"OMass Therapeutics appoints Birgitte Volck as Non-Executive Director\" class=\"state-published\">OMass Therapeutics appoints Birgitte Volck as Non-Executive Director</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">26 February 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">OMass Therapeutics (\u2018OMass\u2019 or \u2018the Company\u2019), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces that Birgitte Volck MD, PhD has joined its Board as a non-executive director.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/oxcan-president-and-co-founder-features-as-guest-speaker-on-thehill-digital-innovation-podcast\" title=\"OXcan President and Co-Founder features as guest speaker on TheHill Digital Innovation Podcast\" class=\"state-published\">OXcan President and Co-Founder features as guest speaker on TheHill Digital Innovation Podcast</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">19 February 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Andreas Halner, president and co-founder of Oxford Cancer Analytics (OXcan), chats to TheHill director, Megan Morys-Carter, about the company's inception, what makes the technology so revolutionary and the ever-increasing success OXcan has met with recently.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/enara-bio-embarks-on-a-research-collaboration-with-george-washington-university-to-deepen-understanding-of-dark-antigen-r-biology-and-expression\" title=\"Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen\u00ae biology and expression\" class=\"state-published\">Enara Bio embarks on a research collaboration with George Washington University to deepen understanding of Dark Antigen\u00ae biology and expression</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=alumni-news\" title=\"Alumni news\">\n\t\t                <span class=\"label label-primary\">Alumni news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">18 February 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Collaboration may inform future combination strategies that can maximise the efficacy of Enara Bio\u2019s pipeline of TCR-based immunotherapies targeting Dark Antigens\u00ae</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/new-2018super-test2019-for-prostate-cancer-developed-in-the-uk-by-edx-medical\" title=\"New \u2018Super Test\u2019 for prostate cancer developed in the UK by EDX Medical\" class=\"state-published\">New \u2018Super Test\u2019 for prostate cancer developed in the UK by EDX Medical</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=tenant-news\" title=\"Tenant news\">\n\t\t                <span class=\"label label-primary\">Tenant news</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">17 February 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">Scientists in Cambridge have developed a new \u2018super test\u2019 for prostate cancer in an effort to revolutionise screening and diagnosis of the disease and accelerate personalised treatment for patients.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n", 
        "\n\n    <div class=\"listing-item listing-item-search\" itemscope itemprop=\"itemListElement\" itemtype=\"http://schema.org/NewsArticle\">\n        \n        <div class=\"media-body\">\n        \n            <h4 class=\"media-heading\">\n                <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/bioescalator-bulletin-2013-annual-review-2023-24-launched\" title=\"Annual Review 2023/24 launched\" class=\"state-published\">Annual Review 2023/24 launched</a>\n            </h4>\n            \n            \n                \n\n    \n    \n        <ul class=\"list-unstyled list-inline categories-list\">\n\t        \n\t        \t\t<li>\n\t\t            <a href=\"https://www.bioescalator.ox.ac.uk/search?category=bioescalator-annual-review\" title=\"BioEscalator annual review\">\n\t\t                <span class=\"label label-primary\">BioEscalator annual review</span>\n\t\t            </a>\n\t\t        </li>\n\t        \n\t   \t</ul>\n\n    \n\n\n            \n\n            \n                <p class=\"details\" itemprop=\"datePublished\">29 January 2025</p>\n            \n                            \n            \n                <p data-truncate=\"yes\" data-truncate-lines=\"2\">The BioEscalator is delighted to have launched its inaugural Annual Review, \u2018Driving innovation, advancing human health \u2019. It provides for the first time a discussion of our achievements in 2023/24, plus the milestones from our initial five years of operation.</p>\n            \n\n            \n                                \n        </div>\n        \n    </div>\n\n\n"
    ], 
    "more": "\n\n    \n        <a href=\"https://www.bioescalator.ox.ac.uk/news-and-events/news/bioarchitech-graduates-from-the-bioescalator-a-new-chapter-for-innovative-cancer-therapy/search?db453715-1a9f-11f1-be65-c7bc867cde1e=&amp;b_start:int=100&amp;tab=newsitem&amp;format=json&amp;random=9b164d11-bf41-4eac-b599-30fe08bfad38\" title=\"Load more\" class=\"btn btn-default load-more-button\">\n            Load More\n        </a>\n    \n\n", 
    "msg": ""
}